Criteria for Drugs Used in Pre-Exposure Prophylaxis Trials against HIV Infection
Open Access
- 7 November 2006
- journal article
- review article
- Published by Public Library of Science (PLoS) in PLoS Medicine
- Vol. 3 (11), e454
- https://doi.org/10.1371/journal.pmed.0030454
Abstract
The authors formulate criteria for an optimal pre-exposure prophylaxis drug candidate, and evaluate existing antiviral drug classes for their suitability.Keywords
This publication has 24 references indexed in Scilit:
- Microbicides to Prevent HIV Transmission: Overcoming Obstacles to Chemical Barrier ProtectionThe Journal of Infectious Diseases, 2006
- Randomized, Controlled Intervention Trial of Male Circumcision for Reduction of HIV Infection Risk: The ANRS 1265 TrialPLoS Medicine, 2005
- Propagation and Dissemination of Infection after Vaginal Transmission of Simian Immunodeficiency VirusJournal of Virology, 2005
- Clinically Relevant Genotype Interpretation of Resistance to DidanosineAntimicrobial Agents and Chemotherapy, 2005
- The Influence of the M184V Mutation in HIV-1 Reverse Transcriptase on the Virological Outcome of Highly Active Antiretroviral Therapy Regimens with Or without DidanosineAntiviral Therapy, 2005
- Diminished Representation of HIV-1 Variants Containing Select Drug Resistance-Conferring Mutations in Primary HIV-1 InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2004
- Efficient inhibition of both syncytium-inducing and non-syncytium-inducing wild-type HIV-1 by lamivudine in vivoAIDS, 1998
- Sexually transmitted diseases enhance HIV transmission: no longer a hypothesisThe Lancet, 1998
- Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patientsAIDS, 1996
- Prevention of SIV Infection in Macaques by ( R )-9-(2-Phosphonylmethoxypropyl)adenineScience, 1995